Loading…
mTOR and MEK1/2 inhibition differentially modulate tumor growth and the immune microenvironment in syngeneic models of oral cavity cancer
We investigated the effects of mTOR and MEK1/2 inhibition on tumor growth and the tumor microenvironment in immunogenic and poorly immunogenic models of murine oral cancer. In vitro, rapamycin and PD901 inhibited signaling through expected downstream targets, but only PD901 reduced viability and alt...
Saved in:
| Published in: | Oncotarget 2015-11, Vol.6 (34), p.36400-36417 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c354t-e59febc9a8916b357863d9b6ebebdfdfe9ecb400439cf2ca2a84f6b416c9d8403 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c354t-e59febc9a8916b357863d9b6ebebdfdfe9ecb400439cf2ca2a84f6b416c9d8403 |
| container_end_page | 36417 |
| container_issue | 34 |
| container_start_page | 36400 |
| container_title | Oncotarget |
| container_volume | 6 |
| creator | Cash, Harrison Shah, Sujay Moore, Ellen Caruso, Andria Uppaluri, Ravindra Van Waes, Carter Allen, Clint |
| description | We investigated the effects of mTOR and MEK1/2 inhibition on tumor growth and the tumor microenvironment in immunogenic and poorly immunogenic models of murine oral cancer. In vitro, rapamycin and PD901 inhibited signaling through expected downstream targets, but only PD901 reduced viability and altered function of MOC cells. Following transplantation of MOC cells into immune-competent mice, effects on both cancer and infiltrating immune cells were characterized following rapamycin and/or PD901 treatment for 21 days. In vivo, both rapamycin and PD901 inhibition reduced primary growth of established MOC tumors on treatment. Following withdrawal of PD901, rapid rebound of tumor growth limited survival, whereas durable tumor control was observed following rapamycin treatment in immunogenic MOC1 tumors despite more robust inhibition of oncogenic signaling by PD901. Characterization of the immune microenvironment revealed diminished infiltration and activation of antigen-specific CD8+ T-cells and other immune cells following PD901 but not rapamycin in immunogenic tumors. Subsequent in vitro T-cell assays validated robust inhibition of T-cell expansion and activation following MEK inhibition compared to mTOR inhibition. CD8 cell depletion abrogated rapamycin-induced primary tumor growth inhibition in MOC1 mice. These data have critical implications in the design of combination targeted and immune therapies in oral cancer. |
| doi_str_mv | 10.18632/oncotarget.5063 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4742185</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1735335730</sourcerecordid><originalsourceid>FETCH-LOGICAL-c354t-e59febc9a8916b357863d9b6ebebdfdfe9ecb400439cf2ca2a84f6b416c9d8403</originalsourceid><addsrcrecordid>eNpVkcFPHCEUxolpo0a9e2o49rI6DDA7XJo0xqrRZpNGzwSYxy7NABaYbfZP8L-Wda3Vd3kvgd_3vrwPoVPSnJG-o-15DCYWlZZQznjT0T10SAQTs5Zz-undfIBOcv7d1OJs3rdiHx20XQUY4Yfoyd8vfmEVBvzz8pact9iFldOuuBjw4KyFBKE4NY4b7OMwjaoALpOPCS9T_FtWL2hZAXbeTwGwdyZFCGuXYvAVrXo4b8ISAjizlYAx42hxTGrERq1d2dQWDKRj9NmqMcPJaz9CDz8u7y-uZ3eLq5uL73czQzkrM-DCgjZC9YJ0mvJ5PcUgdAca9GAHCwKMZk3DqDC2NapVPbOdZqQzYuhZQ4_Qt53u46Q9DKaarF7kY3JepY2MysmPL8Gt5DKuJZuzlvS8Cnx9FUjxzwS5SO-ygXFUAeKUJZlTTqsxut3V7L7Wo-ScwL6tIY18CVH-D1FuQ6zIl_f23oB_kdFnBsyfwA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1735335730</pqid></control><display><type>article</type><title>mTOR and MEK1/2 inhibition differentially modulate tumor growth and the immune microenvironment in syngeneic models of oral cavity cancer</title><source>PubMed Central（OA）</source><creator>Cash, Harrison ; Shah, Sujay ; Moore, Ellen ; Caruso, Andria ; Uppaluri, Ravindra ; Van Waes, Carter ; Allen, Clint</creator><creatorcontrib>Cash, Harrison ; Shah, Sujay ; Moore, Ellen ; Caruso, Andria ; Uppaluri, Ravindra ; Van Waes, Carter ; Allen, Clint</creatorcontrib><description>We investigated the effects of mTOR and MEK1/2 inhibition on tumor growth and the tumor microenvironment in immunogenic and poorly immunogenic models of murine oral cancer. In vitro, rapamycin and PD901 inhibited signaling through expected downstream targets, but only PD901 reduced viability and altered function of MOC cells. Following transplantation of MOC cells into immune-competent mice, effects on both cancer and infiltrating immune cells were characterized following rapamycin and/or PD901 treatment for 21 days. In vivo, both rapamycin and PD901 inhibition reduced primary growth of established MOC tumors on treatment. Following withdrawal of PD901, rapid rebound of tumor growth limited survival, whereas durable tumor control was observed following rapamycin treatment in immunogenic MOC1 tumors despite more robust inhibition of oncogenic signaling by PD901. Characterization of the immune microenvironment revealed diminished infiltration and activation of antigen-specific CD8+ T-cells and other immune cells following PD901 but not rapamycin in immunogenic tumors. Subsequent in vitro T-cell assays validated robust inhibition of T-cell expansion and activation following MEK inhibition compared to mTOR inhibition. CD8 cell depletion abrogated rapamycin-induced primary tumor growth inhibition in MOC1 mice. These data have critical implications in the design of combination targeted and immune therapies in oral cancer.</description><identifier>ISSN: 1949-2553</identifier><identifier>EISSN: 1949-2553</identifier><identifier>DOI: 10.18632/oncotarget.5063</identifier><identifier>PMID: 26506415</identifier><language>eng</language><publisher>United States: Impact Journals LLC</publisher><subject>Animals ; Female ; MAP Kinase Kinase 1 - antagonists & inhibitors ; MAP Kinase Kinase 1 - metabolism ; MAP Kinase Kinase 2 - antagonists & inhibitors ; MAP Kinase Kinase 2 - metabolism ; Mice ; Mice, Inbred C57BL ; Mouth Neoplasms - drug therapy ; Mouth Neoplasms - enzymology ; Mouth Neoplasms - metabolism ; Protein Kinase Inhibitors - pharmacology ; Research Paper ; Signal Transduction - drug effects ; Sirolimus - pharmacology ; TOR Serine-Threonine Kinases - antagonists & inhibitors ; TOR Serine-Threonine Kinases - metabolism ; Tumor Microenvironment</subject><ispartof>Oncotarget, 2015-11, Vol.6 (34), p.36400-36417</ispartof><rights>Copyright: © 2015 Cash et al. 2015</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c354t-e59febc9a8916b357863d9b6ebebdfdfe9ecb400439cf2ca2a84f6b416c9d8403</citedby><cites>FETCH-LOGICAL-c354t-e59febc9a8916b357863d9b6ebebdfdfe9ecb400439cf2ca2a84f6b416c9d8403</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742185/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742185/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,733,786,790,891,27957,27958,53827,53829</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26506415$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cash, Harrison</creatorcontrib><creatorcontrib>Shah, Sujay</creatorcontrib><creatorcontrib>Moore, Ellen</creatorcontrib><creatorcontrib>Caruso, Andria</creatorcontrib><creatorcontrib>Uppaluri, Ravindra</creatorcontrib><creatorcontrib>Van Waes, Carter</creatorcontrib><creatorcontrib>Allen, Clint</creatorcontrib><title>mTOR and MEK1/2 inhibition differentially modulate tumor growth and the immune microenvironment in syngeneic models of oral cavity cancer</title><title>Oncotarget</title><addtitle>Oncotarget</addtitle><description>We investigated the effects of mTOR and MEK1/2 inhibition on tumor growth and the tumor microenvironment in immunogenic and poorly immunogenic models of murine oral cancer. In vitro, rapamycin and PD901 inhibited signaling through expected downstream targets, but only PD901 reduced viability and altered function of MOC cells. Following transplantation of MOC cells into immune-competent mice, effects on both cancer and infiltrating immune cells were characterized following rapamycin and/or PD901 treatment for 21 days. In vivo, both rapamycin and PD901 inhibition reduced primary growth of established MOC tumors on treatment. Following withdrawal of PD901, rapid rebound of tumor growth limited survival, whereas durable tumor control was observed following rapamycin treatment in immunogenic MOC1 tumors despite more robust inhibition of oncogenic signaling by PD901. Characterization of the immune microenvironment revealed diminished infiltration and activation of antigen-specific CD8+ T-cells and other immune cells following PD901 but not rapamycin in immunogenic tumors. Subsequent in vitro T-cell assays validated robust inhibition of T-cell expansion and activation following MEK inhibition compared to mTOR inhibition. CD8 cell depletion abrogated rapamycin-induced primary tumor growth inhibition in MOC1 mice. These data have critical implications in the design of combination targeted and immune therapies in oral cancer.</description><subject>Animals</subject><subject>Female</subject><subject>MAP Kinase Kinase 1 - antagonists & inhibitors</subject><subject>MAP Kinase Kinase 1 - metabolism</subject><subject>MAP Kinase Kinase 2 - antagonists & inhibitors</subject><subject>MAP Kinase Kinase 2 - metabolism</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Mouth Neoplasms - drug therapy</subject><subject>Mouth Neoplasms - enzymology</subject><subject>Mouth Neoplasms - metabolism</subject><subject>Protein Kinase Inhibitors - pharmacology</subject><subject>Research Paper</subject><subject>Signal Transduction - drug effects</subject><subject>Sirolimus - pharmacology</subject><subject>TOR Serine-Threonine Kinases - antagonists & inhibitors</subject><subject>TOR Serine-Threonine Kinases - metabolism</subject><subject>Tumor Microenvironment</subject><issn>1949-2553</issn><issn>1949-2553</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNpVkcFPHCEUxolpo0a9e2o49rI6DDA7XJo0xqrRZpNGzwSYxy7NABaYbfZP8L-Wda3Vd3kvgd_3vrwPoVPSnJG-o-15DCYWlZZQznjT0T10SAQTs5Zz-undfIBOcv7d1OJs3rdiHx20XQUY4Yfoyd8vfmEVBvzz8pact9iFldOuuBjw4KyFBKE4NY4b7OMwjaoALpOPCS9T_FtWL2hZAXbeTwGwdyZFCGuXYvAVrXo4b8ISAjizlYAx42hxTGrERq1d2dQWDKRj9NmqMcPJaz9CDz8u7y-uZ3eLq5uL73czQzkrM-DCgjZC9YJ0mvJ5PcUgdAca9GAHCwKMZk3DqDC2NapVPbOdZqQzYuhZQ4_Qt53u46Q9DKaarF7kY3JepY2MysmPL8Gt5DKuJZuzlvS8Cnx9FUjxzwS5SO-ygXFUAeKUJZlTTqsxut3V7L7Wo-ScwL6tIY18CVH-D1FuQ6zIl_f23oB_kdFnBsyfwA</recordid><startdate>20151103</startdate><enddate>20151103</enddate><creator>Cash, Harrison</creator><creator>Shah, Sujay</creator><creator>Moore, Ellen</creator><creator>Caruso, Andria</creator><creator>Uppaluri, Ravindra</creator><creator>Van Waes, Carter</creator><creator>Allen, Clint</creator><general>Impact Journals LLC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20151103</creationdate><title>mTOR and MEK1/2 inhibition differentially modulate tumor growth and the immune microenvironment in syngeneic models of oral cavity cancer</title><author>Cash, Harrison ; Shah, Sujay ; Moore, Ellen ; Caruso, Andria ; Uppaluri, Ravindra ; Van Waes, Carter ; Allen, Clint</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c354t-e59febc9a8916b357863d9b6ebebdfdfe9ecb400439cf2ca2a84f6b416c9d8403</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Animals</topic><topic>Female</topic><topic>MAP Kinase Kinase 1 - antagonists & inhibitors</topic><topic>MAP Kinase Kinase 1 - metabolism</topic><topic>MAP Kinase Kinase 2 - antagonists & inhibitors</topic><topic>MAP Kinase Kinase 2 - metabolism</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Mouth Neoplasms - drug therapy</topic><topic>Mouth Neoplasms - enzymology</topic><topic>Mouth Neoplasms - metabolism</topic><topic>Protein Kinase Inhibitors - pharmacology</topic><topic>Research Paper</topic><topic>Signal Transduction - drug effects</topic><topic>Sirolimus - pharmacology</topic><topic>TOR Serine-Threonine Kinases - antagonists & inhibitors</topic><topic>TOR Serine-Threonine Kinases - metabolism</topic><topic>Tumor Microenvironment</topic><toplevel>online_resources</toplevel><creatorcontrib>Cash, Harrison</creatorcontrib><creatorcontrib>Shah, Sujay</creatorcontrib><creatorcontrib>Moore, Ellen</creatorcontrib><creatorcontrib>Caruso, Andria</creatorcontrib><creatorcontrib>Uppaluri, Ravindra</creatorcontrib><creatorcontrib>Van Waes, Carter</creatorcontrib><creatorcontrib>Allen, Clint</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncotarget</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cash, Harrison</au><au>Shah, Sujay</au><au>Moore, Ellen</au><au>Caruso, Andria</au><au>Uppaluri, Ravindra</au><au>Van Waes, Carter</au><au>Allen, Clint</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>mTOR and MEK1/2 inhibition differentially modulate tumor growth and the immune microenvironment in syngeneic models of oral cavity cancer</atitle><jtitle>Oncotarget</jtitle><addtitle>Oncotarget</addtitle><date>2015-11-03</date><risdate>2015</risdate><volume>6</volume><issue>34</issue><spage>36400</spage><epage>36417</epage><pages>36400-36417</pages><issn>1949-2553</issn><eissn>1949-2553</eissn><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><abstract>We investigated the effects of mTOR and MEK1/2 inhibition on tumor growth and the tumor microenvironment in immunogenic and poorly immunogenic models of murine oral cancer. In vitro, rapamycin and PD901 inhibited signaling through expected downstream targets, but only PD901 reduced viability and altered function of MOC cells. Following transplantation of MOC cells into immune-competent mice, effects on both cancer and infiltrating immune cells were characterized following rapamycin and/or PD901 treatment for 21 days. In vivo, both rapamycin and PD901 inhibition reduced primary growth of established MOC tumors on treatment. Following withdrawal of PD901, rapid rebound of tumor growth limited survival, whereas durable tumor control was observed following rapamycin treatment in immunogenic MOC1 tumors despite more robust inhibition of oncogenic signaling by PD901. Characterization of the immune microenvironment revealed diminished infiltration and activation of antigen-specific CD8+ T-cells and other immune cells following PD901 but not rapamycin in immunogenic tumors. Subsequent in vitro T-cell assays validated robust inhibition of T-cell expansion and activation following MEK inhibition compared to mTOR inhibition. CD8 cell depletion abrogated rapamycin-induced primary tumor growth inhibition in MOC1 mice. These data have critical implications in the design of combination targeted and immune therapies in oral cancer.</abstract><cop>United States</cop><pub>Impact Journals LLC</pub><pmid>26506415</pmid><doi>10.18632/oncotarget.5063</doi><tpages>18</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1949-2553 |
| ispartof | Oncotarget, 2015-11, Vol.6 (34), p.36400-36417 |
| issn | 1949-2553 1949-2553 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4742185 |
| source | PubMed Central（OA） |
| subjects | Animals Female MAP Kinase Kinase 1 - antagonists & inhibitors MAP Kinase Kinase 1 - metabolism MAP Kinase Kinase 2 - antagonists & inhibitors MAP Kinase Kinase 2 - metabolism Mice Mice, Inbred C57BL Mouth Neoplasms - drug therapy Mouth Neoplasms - enzymology Mouth Neoplasms - metabolism Protein Kinase Inhibitors - pharmacology Research Paper Signal Transduction - drug effects Sirolimus - pharmacology TOR Serine-Threonine Kinases - antagonists & inhibitors TOR Serine-Threonine Kinases - metabolism Tumor Microenvironment |
| title | mTOR and MEK1/2 inhibition differentially modulate tumor growth and the immune microenvironment in syngeneic models of oral cavity cancer |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T12%3A36%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=mTOR%20and%20MEK1/2%20inhibition%20differentially%20modulate%20tumor%20growth%20and%20the%20immune%20microenvironment%20in%20syngeneic%20models%20of%20oral%20cavity%20cancer&rft.jtitle=Oncotarget&rft.au=Cash,%20Harrison&rft.date=2015-11-03&rft.volume=6&rft.issue=34&rft.spage=36400&rft.epage=36417&rft.pages=36400-36417&rft.issn=1949-2553&rft.eissn=1949-2553&rft_id=info:doi/10.18632/oncotarget.5063&rft_dat=%3Cproquest_pubme%3E1735335730%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c354t-e59febc9a8916b357863d9b6ebebdfdfe9ecb400439cf2ca2a84f6b416c9d8403%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1735335730&rft_id=info:pmid/26506415&rfr_iscdi=true |